SSI Diagnostica
Webshop Change language
SSI Diagnostica

category: QFT TB

QuantiFERON® Monitor

QuantiFERON Monitor (QFM) is an in vitro diagnostic test that detects interferon-γ (IFNγ) following incubation of heparinized whole blood with innate and adaptive immune response stimulants.

Clinical relevance

QuantiFERON Monitor (QFM) is an in vitro diagnostic test detecting interferon-γ (IFNγ) following incubation of heparinized whole blood with innate and adaptive immune response stimulants.

Product description

The assay is used to detect cell mediated immune response in immunosuppressed solid organ transplant patients.

QuantiFERON Monitor is intended for use in conjunction with risk assessment and other medical and diagnostic evaluations.

Benefits

  • Assesses cell-mediated immune (CMI) response
  • Provides nonpathogen-specific immune monitoring
  • Complements pathogen-specific monitoring
  • Aids in clinical management of solid organ transplant patients

Maintain the optimal therapeutic window for your patients

Find the right balance with QuantiFERON Monitor

Providing insight into your patients’ immune status

Patient immunosuppression is a necessity for successful solid organ transplantation.

Other interesting content

Looking for something else? You might be interested in this as well.

QuantiFERON® reasearch papers – Follow the latest studies

Latest research applications of T cell assays in SARS-CoV-2 infections, immunity investigations and patient monitoring

Read more

QFT-CMV

QFT CMV – Monitor transplant patient’s level of anti-CMV immunity

QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test is used to monitor people’s risks of developing CMV disease and can be used in connection with organ transplants to predict whether patients have an increased risk of developing CMV disease.

Read more

Contact

Please, reach out if you have questions, comments or requests.



    QFT-CMV

    QuantiFERON® – CMV

    QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test is used to monitor people’s risks of developing CMV disease and can be used in connection with organ transplants to predict whether patients have an increased risk of developing CMV disease.

    Clinical relevance

    Human cytomegalovirus (CMV) is a herpes virus that infects between 50 and 85% of the adult population in the world. It is the most common virus that pregnant women can pass on to the unborn child, and which is responsible for 1 in 750 children being born with or developing disabilities as a result of the virus. CMV is an infectious pathogen associated with organ transplantation. In connection with transplantation, CMV is associated with increased disease and death.

    QuantiFERON® – CMV has been developed to monitor individuals’ risks of developing CMV disease. In connection with organ transplants, the test can be used to predict whether patients have an increased risk of developing CMV disease and can thus support the clinician in the therapeutic treatment of these patients after the operation.

    Product description

    QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test requires the collection of three 1 mL blood samples in special antigen-coated sample tubes with subsequent ELISA analysis in the laboratory. The ELISA measures IFN gamma as a marker of a person’s ability to protect themselves against viral infection.

    SSI Diagnostica distributes QuantiFERON® CMV in Denmark, Iceland, Norway and Sweden on behalf of QIAGEN, which has developed and manufactured the test.

    Benefits

    • QFN CMV is the only commercial test for monitoring cellular immunity specific to CMV.
    • QFN CMV is a simple test that only requires 3 x 1 mL blood samples with subsequent laboratory analysis.
    • QFN CMV is a rapid test with results within 24 hours.
    • QFN CMV can predict the likelihood of developing CMV disease and assist in the clinical and therapeutic treatment of transplant patients 

    Predict risk of new and recurrent CMV disease

    Monitor transplant patient’s level of anti-CMV immunity

    Determine both pre- and posttransplant CMV-risk stratification

    Guide therapeutic decision making 

    Other interesting content

    Looking for something else? You might be interested in this as well.

    QFT-CMV

    QFT-CMV – Monitor transplant patient’s level of anti-CMV immunity

    QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test is used to monitor people’s risks of developing CMV disease and can be used in connection with organ transplants to predict whether patients have an increased risk of developing CMV disease.

    Read more

    QFT-TB Gold Plus – Detect TB with confidence

    QuantiFERON® TB-Gold Plus is an ELISA test for the detection of M. tuberculosis in immunocompetent individuals. The analysis is particularly relevant in those who have received the BCG vaccine, as the analysis, in contrast to skin tests with tuberculin (Mantoux), can distinguish between infection with M. tuberculosis and vaccination.

    Read more

    Contact

    Please, reach out if you have questions, comments or requests.



      QuantiFERON® TB-Gold Plus

      QuantiFERON® TB-Gold Plus is an ELISA test for the detection of M. tuberculosis in immunocompetent individuals. The analysis is particularly relevant in those who have received the BCG vaccine, as the analysis, in contrast to skin tests with tuberculin (Mantoux), can distinguish between infection with M. tuberculosis and vaccination.

      Clinical relevance

      QuantiFERON® TB-Gold Plus is an ELISA test for the detection of M. tuberculosis in immunocompetent individuals, for example, as part of infection detection, screening of high-risk groups, in special cases for the detection of active tuberculous disease and before treatment with immunosuppressive drugs. In the case of infection with M. tuberculosis, the immune response is predominantly cell mediated. In infected immunocompetent individuals, stimulation of blood with specific antigens (ESAT 6, CFP 10 and TB 7.7) will cause T lymphocytes to release the cytokine interferon gamma, which is detected by ELISA.

      Product description

      QuantiFERON® TB-Gold Plus consists of an ELISA kit and blood collection tubes, which can be ordered separately. For sampling, four blood collection tubes are used: 1x Nil; 2x TB Ag and 1x Mitogen. The tubes are delivered as a combined package or in bulk. In the laboratory, up to 58 tests can be performed per ELISA kit. SSI Diagnostica distributes QuantiFERON®TB-Gold Plus in Denmark, Iceland, Norway and Sweden on behalf of QIAGEN.

      Benefits

      • Detection of infection with M. tuberculosis
      • Result within 24 hours
      • Distinguishes between infection with M. tuberculosis and BCG vaccination
      • Can be easily repeated – no booster phenomenon
      • Only one patient visit (compared to Mantoux test)
      • High reproducibility
      • Objective reading (95% CI 98-100%)
      • >99% specificity and >89% (95% CI 83-93%) sensitivity

      Detect TB with confidence – more than 1700 clinical and scientific studies

      Advancing the science of TB testing with innovative CD8 +T-cell technology

      Highest specificity of any test for tuberculosis infection

      For use as an aid in the detection of Mycobacterium tuberculosis (TB) infection

      Other interesting content

      Looking for something else? You might be interested in this as well.

      QuantiFERON® reasearch papers – Follow the latest studies

      Latest research applications of T cell assays in SARS-CoV-2 infections, immunity investigations and patient monitoring

      Read more

      QFT CMV – Monitor transplant patient’s level of anti-CMV immunity

      QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test is used to monitor people’s risks of developing CMV disease and can be used in connection with organ transplants to predict whether patients have an increased risk of developing CMV disease.

      Read more

      Contact

      Please, reach out if you have questions, comments or requests.